Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metrizoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metrizoic Acid SCHEMBL1237977 | 0.99 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNAKDM4ECYP2C19HIF1A | |
| Metrizoic Acid SCHEMBL30869169 | 0.99 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNAKDM4ECYP2C19HIF1A | |
| Diatrizoic Acid SCHEMBL107036 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4EHIF1A | |
| Diatrizoic Acid SCHEMBL1685085 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4EHIF1A | |
| Diatrizoic Acid SCHEMBL720469 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4EHIF1A | |
| Diatrizoic Acid SCHEMBL468613 | 0.86 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4EHIF1A | |
| Diatrizoic Acid SCHEMBL2501947 | 0.86 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4EHIF1A | |
| Metrizoic Acid SCHEMBL1236887 | 0.82 | LMNA (0.51) | SMN1; SMN2LMNA | |
| Iothalamic Acid SCHEMBL29488709 | 0.82 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4ECYP2C19HIF1A | |
| Iothalamic Acid SCHEMBL180546 | 0.82 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4ECYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126788-B1 | SYSTEM FOR RADIOGRAPHIC IMAGING OF TISSUE | VERITAS PHARMACEUTICALS (US) | 2011-08-24 | — | — | EP | disclosed |
| US-6923950-B2 | System and method for radiographic imaging of tissue | VERITAS PHARMACEUTICALS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040170561-A1 | Functional radiographic imaging methods and agents | SALB JESSE (US) | 2004-09-02 | — | — | US | disclosed |
| US-6723746-B2 | CELL MEMBRANE-PERMEABLE, RADIO-OPAQUE IMAGING AGENT | VERITAS PHARMACEUTICALS, INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030091508-A1 | System and method for radiographic imaging of tissue | VERITAS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| EP-1263478-A2 | FUNCTIONAL RADIOGRAPHIC IMAGING METHODS AND AGENTS | Veritas Pharmaceuticals (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20010031035-A1 | Functional radiographic imaging methods and agents | VERITAS PHARMACEUTICALS INC. | 2001-10-18 | — | — | US | disclosed |
| WO-2001068151-A2 | FUNCTIONAL RADIOGRAPHIC IMAGING METHODS AND AGENTS | VERITAS PHARMACEUTICALS (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-1126788-A2 | SYSTEM AND METHOD FOR RADIOGRAPHIC IMAGING OF TISSUE | Veritas Pharmaceuticals (US) | 2001-08-29 | — | — | EP | disclosed |
| US-20010001011-A1 | System and method for radiographic imaging of tissue | SALB JESSE (US) | 2001-05-10 | — | — | US | disclosed |
| US-6226352-B1 | System and method for radiographic imaging of tissue | VERITAS PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2000013590-A2 | SYSTEM AND METHOD FOR RADIOGRAPHIC IMAGING OF TISSUE | VERITAS PHARMACEUTICALS (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040170561-A1 | Functional radiographic imaging methods and agents | GPR180, TMEM120A, RXFP1 | SMN1; SMN2 2355/4885LMNA 730/4885KDM4E 4087/4885 |
| US-20010001011-A1 | System and method for radiographic imaging of tissue | HK1, HK2, SLC2A8 | SMN1; SMN2 2513/4885LMNA 1428/4885KDM4E 3363/4885 |
| US-20030091508-A1 | System and method for radiographic imaging of tissue | HK1, HK2, SLC2A8 | SMN1; SMN2 2513/4885LMNA 1428/4885KDM4E 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.